Education

1992-1996     McGill University, Montreal, Canada; MDCM

1989-1992     McGill University, Montreal Canada; BS

Postdoctoral Training

2002-2005     Masters Degree in Epidemiology 
                      and Biostatistcs.

2000-2002     Research Fellow, Tufts University School of
                      Medicine, Boston, MA

1999-2002     Hematology/Oncology Fellowship,
                      Tufts University, Boston MA

1996-1999     Queens University postgraduate education
                       in Internal Medicine (Kingston General & Hotel
                       Dieu Hospitals, Kingston, Ontario)

Academic Interests

These include clinical research around adjuvant treatment options for patients with esophageal and stomach cancers, supportive care for patients undergoing abdominal radiation therapy including novel combinations of antiemetics in this setting (AVERT trial: NCT00970905), and the protective impact of lipid lowering  agents called statins on the risk of venous blood clots in patients with advanced cancer. I also participate in many national cooperative group trials covering the cancer sites listed above.

Publications

For a complete list of Steven Ades' publication, please visit Google Scholar

Ng HK, Rogala BG, Ades S, Schwartz JR, Ashikaga T, Vacek P, Holmes CE. Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation. J Oncol Pharm Pract. 2020 Feb 11: 1078155220901569. doi: 10.1177/1078155220901569. PMID: 32046579

Douce DR, Holmes CE, Cushman M, MacLean C, Ades S, Zakai NA. Risk Factors for Cancer-Associated Venous Thromboembolism: the Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic (VTE-PAAC) Study. J Thromb Haemost. 2019 Aug 18. doi: 10.1111/jth.14614. PMID: 31423717

Yang MX, Coates RF, Ambaye A, Cortright V, Mitchell JM, Buskey AM, Zubarik R, Liu JG, Ades S, Barry MM. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomark Res. 2018 Apr 18,6:15. doi: 10.1186/s40364-018-0129-8. eCollections 2018 PMID: 29713473

Farina NH, Zingiryan A, Vrolijk MA, Perrapato SD, Ades S, Stein GS, Lian JB, Landry CL. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. 2018 Sep; 233(9): 6408-6417. doi: 10.1002/jcp.26593. PMID: 29663383

Ades S, Douce D, Holmes CE, Cory S, Prior S, Butenas S, Callas P, Cushman M. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer. J Thromb Haemost. 2018 Mar 25. doi: 10.1111/jth.14004. PMID: 29575637

L. E. Ferri*, S. Ades*, T. Alcindor, M.R. Chasen, V. Marcus, M. Hickeson, G. Artho, M. P. Thirlwell. Peri-Operative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A Multi-Center Phase II Trial. Ann Oncol; 23, 1512-1517, 2011 Oct 29.

(*Co-primary authorship Ferri & Ades) 

Ades S. Adjuvant therapy for colon cancer in the elderly.  Oncology 23(2):162-7, 2009.

Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco E (for the Biomarkers of Cervical Cancer Risk Study Team).Selected Class I and Class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia.  Int J Cancer 122(12):2820-6, 2008.

Ades S, Maxfield LF, Gould CJ, Jones GK, Levy SB. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors, Int J Oncol 28(3): 747-53, 2006